{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:03:16Z","timestamp":1784782996814,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Municipal Health Commission high-level public health technical personnel construction project","award":["discipline leader-03-26"],"award-info":[{"award-number":["discipline leader-03-26"]}]},{"name":"Beijing Hospital\u2019s Authority \u201cpeak\u201d talent training program","award":["DFL20241803"],"award-info":[{"award-number":["DFL20241803"]}]},{"name":"Beijing Hospital\u2019s Authority Clinical medicine Development of special funding support","award":["ZLRK202301"],"award-info":[{"award-number":["ZLRK202301"]}]},{"name":"Beijing Research Ward Excellence Program","award":["BRWEP2024W102170101"],"award-info":[{"award-number":["BRWEP2024W102170101"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-1-2172"],"award-info":[{"award-number":["2022-1-2172"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2306900"],"award-info":[{"award-number":["2023YFC2306900"]}]},{"name":"National Key Research and Development Program of the Ministry of Science and Technology","award":["2023YFC2308105"],"award-info":[{"award-number":["2023YFC2308105"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2022YFC2603500"],"award-info":[{"award-number":["2022YFC2603500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2022YFC2603505"],"award-info":[{"award-number":["2022YFC2603505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The aim of this study was to evaluate the efficacy and safety of avatrombopag in patients with chronic liver disease (CLD) and thrombocytopenia scheduled for elective invasive\/minimally invasive procedures, providing clinical guidance for patients requiring platelet (PLT) elevation. Methods: In this single-center, prospective study, patients with CLD and PLT counts &lt;50 \u00d7 109\/L were scheduled for elective invasive\/minimally invasive surgery, receiving 5-day avatrombopag plus standard CLD management. PLT response, dynamics, and safety were assessed. Results: A total of 108 patients with CLD and baseline PLT counts &lt;50 \u00d7 109\/L were enrolled, showing an 83.33% response rate. Responders exhibited significantly higher baseline white blood cell (WBC, p = 0.009), neutrophil (p = 0.016), hemoglobin (HGB, p = 0.011), and PLT (p = 0.001) levels compared to non-responders. Baseline PLT correlated positively with age (p = 0.014), WBC (p = 0.046), HGB (p = 0.001), and prothrombin activity (p = 0.023). Logistic regression identified baseline PLT as an independent predictor of treatment response (p = 0.002). PLT began rising by day 5 post-treatment, peaked around day 10, and declined to baseline by day 40 in overall cases and responders. Non-responders showed only mild PLT elevation by day 5 (remaining &lt;50 \u00d7 109\/L), with no further increase by day 10. No adverse events were observed. No thrombotic or bleeding events were recorded in this small cohort; however, the limited sample size precludes definitive conclusions on thrombosis risk. Conclusions: Avatrombopag demonstrated high efficacy and favorable safety for elevating PLT in patients with CLD, with a higher baseline PLT predicting a better response.<\/jats:p>","DOI":"10.3390\/jcm15145715","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:35:52Z","timestamp":1784630152000},"page":"5715","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Avatrombopag in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Elective Surgery"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-5803","authenticated-orcid":false,"given":"Weihua","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiao","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjiao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing 100015, China"},{"name":"Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China"},{"name":"HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing 100015, China"},{"name":"Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9138195","DOI":"10.1155\/2022\/9138195","article-title":"Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges","volume":"2022","author":"Huang","year":"2022","journal-title":"J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1111\/j.1572-0241.2002.05845.x","article-title":"Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection","volume":"97","author":"Pockros","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e35208","DOI":"10.1097\/MD.0000000000035208","article-title":"Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure","volume":"102","author":"Satapathy","year":"2023","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia","volume":"367","author":"Afdhal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.4240\/wjgs.v14.i11.1260","article-title":"Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study","volume":"14","author":"Ding","year":"2022","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1097\/JS9.0000000000002899","article-title":"The application of avatrombopag in chronic liver disease patients with severe thrombocytopenia undergoing procedures in China: A prospective real-world cohort study","volume":"111","author":"Xiao","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_7","first-page":"1225","article-title":"[Use of Thrombopoetin-Receptor-Agonists (TPO-RA) in patients with liver cirrhosis before invasive procedures]","volume":"61","author":"Mucke","year":"2023","journal-title":"Z. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e31429","DOI":"10.1097\/MD.0000000000031429","article-title":"A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series","volume":"101","author":"Biolato","year":"2022","journal-title":"Medicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jhep.2010.08.018","article-title":"Platelet production and destruction in liver cirrhosis","volume":"54","author":"Pradella","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/08971900221125827","article-title":"Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease","volume":"37","author":"Tran","year":"2024","journal-title":"J. Pharm. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11262","DOI":"10.1038\/s41598-024-62129-5","article-title":"Data mining and safety analysis of avatrombopag: A retrospective pharmacovigilance study based on the US food and drug administration\u2019s adverse event reporting system","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia","volume":"155","author":"Terrault","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28488","DOI":"10.1038\/s41598-024-80067-0","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag","volume":"14","author":"Xue","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/hematolrep15030054","article-title":"Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag","volume":"15","author":"Abdelsamia","year":"2023","journal-title":"Hematol. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.2169\/internalmedicine.4822-24","article-title":"Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and Its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study","volume":"64","author":"Manabe","year":"2025","journal-title":"Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000539006","article-title":"Lusutrombopag Reduces the Risk of Hemoperitoneum Caused by Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Compared with Platelet Transfusion","volume":"42","author":"Taki","year":"2024","journal-title":"Dig. Dis."},{"key":"ref_18","first-page":"762","article-title":"Genetic Variations and Nonalcoholic Fatty Liver Disease: Field Synopsis, Systematic Meta-Analysis, and Epidemiological Evidence","volume":"37","author":"Li","year":"2024","journal-title":"Biomed. Environ. Sci."},{"key":"ref_19","first-page":"1123","article-title":"An Artificial Neural Network Model Combined with Dietary Retinol Intake from Different Sources to Predict the Risk of Nonalcoholic Fatty Liver Disease","volume":"36","author":"Liu","year":"2023","journal-title":"Biomed. Environ. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): An open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2022.09.005","article-title":"Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis","volume":"78","author":"Zanetto","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Craciun, R., Buliarca, A., Matei, D., Grapa, C., Nenu, I., Stefanescu, H., Mocan, T., Procopet, B., and Sparchez, Z. (2024). Cirrhosis Progression Is Not Associated with Clinically Significant Alterations in Global Hemostasis Assessed by Thromboelastography. J. Clin. Med., 13.","DOI":"10.1016\/S0168-8278(23)00807-3"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.gastrohep.2023.05.010","article-title":"Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing","volume":"47","author":"Jarque","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5421632","DOI":"10.1155\/2020\/5421632","article-title":"Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies","volume":"2020","author":"Poordad","year":"2020","journal-title":"Int. J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, Y.S., Wang, W., Zhang, S., Zhang, S.Y., Shen, A.Z., Wang, W., Song, H.C., Yao, H.Z., Song, R.P., and Meng, F.Z. (2022). Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1009612"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/hepr.13755","article-title":"Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia","volume":"52","author":"Eguchi","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","article-title":"Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures","volume":"28","author":"Gallo","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/hematology.2022000408","article-title":"Thrombocytopenia and liver disease: Pathophysiology and periprocedural management","volume":"2022","author":"Lim","year":"2022","journal-title":"Hematol. AM. Soc. Hematol. Educ. Program"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.21873\/invivo.13561","article-title":"Risk Factors for Thrombocytopenia Induced by Capecitabine Plus Oxaliplatin Therapy in Patients with Colorectal Cancer","volume":"38","author":"Kato","year":"2024","journal-title":"In Vivo"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10760296261431920","DOI":"10.1177\/10760296261431920","article-title":"Avatrombopag and Platelet Recovery in Sepsis-Associated Thrombocytopenia: A Retrospective Observational Cohort Study","volume":"32","author":"Shi","year":"2026","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1272\/jnms.JNMS.2020_87-603","article-title":"The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function","volume":"87","author":"Takeuchi","year":"2021","journal-title":"J. Nippon Med. Sch."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5715\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:31:59Z","timestamp":1784781119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":31,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145715"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145715","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}